Jefferies Financial Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Free Report) from a hold rating to a strong-buy rating in a research report report published on Tuesday,Zacks.com reports.
Several other equities analysts also recently commented on the stock. The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 15th. Zacks Research upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research note on Monday, May 25th. Two investment analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy”.
Check Out Our Latest Report on SGIOY
Shionogi & Co., Ltd. Unsponsored ADR Stock Down 2.6%
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.03. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.08% and a return on equity of 13.56%. The firm had revenue of $881.71 million during the quarter, compared to analysts’ expectations of $895.52 million. Analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.8 earnings per share for the current fiscal year.
About Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.
The company’s product portfolio spans both established and innovative therapies.
Featured Articles
- Five stocks we like better than Shionogi & Co., Ltd. Unsponsored ADR
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
